Promising Phase II Data For Sanofi’s Hemlibra Rival Fitusiran
Gene Therapy Also Approaching Market
Sanofi has unveiled encouraging Phase II data for fitusiran, a novel RNA-based hemophilia therapy which could eventually challenge Roche’s blockbuster Hemlibra.
